Breaking News, Collaborations & Alliances

Catalent, SELLAS in Drug Development and Mfg. Pact

Will support the development and reprofiling of zolpidem using Catalent’s OSDrC OptiDose

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent Pharma Solutions has entered an exclusive development and licensing agreement with Swiss-based SELLAS Life Sciences Group to support the development and therapeutic reprofiling of zolpidem using Catalent’s OSDrC OptiDose drug delivery technology.   The companies will work together to repurpose zolpidem, an imidazopyridine drug currently used for the treatment of insomnia, for the treatment of Parkinson’s Disease (PD) and the orphan indication Progressive Supranuclear Palsy (PSP). Catale...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters